Key Documents

View All Documentation

SML0015

SR 142948A

Name: SR 142948A
Brand: SIGMA

≥98% (HPLC), Neurotensin receptor antagonist, powder

Synonym(s):

2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole3-carbonyl]amino] adamantane-2-carboxylic acid hydrochloride, SR 142948 hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₃₉H₅₁N₅O₆·HCl

CAS Number:

184162-21-8

Molecular Weight:

722.31

UNSPSC Code:

12352200

PubChem Substance ID:

329825090

NACRES:

NA.77

MDL number:

MFCD03106502

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

SR 142948A, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H₂O: ≥2 mg/mL at warmed to 60 °C

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

Cl.COc1cccc(OC)c1-c2cc(nn2-c3ccc(cc3C(C)C)C(=O)N(C)CCCN(C)C)C(=O)NC4([C@@H]5C[C@H]6C[C@@H](C5)C[C@@H]4C6)C(O)=O

InChI

1S/C39H51N5O6.ClH/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24;/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48);1H/t24-,25+,27-,28+,39?;

InChI key

CUYNEHGBVHUQQW-BVJGGMLGSA-N

Related Categories

Bioactive Small Molecules

Application

SR 142948A was used to study the role of neurotensin signaling in intracellular alkanization and expression of IL-8 in human pancreatic cancer cells.

Biochem/physiol Actions

SR 142948A is a neurotensin receptor antagonist

SR 142948A is a non-peptide Neurotensin receptor antagonist

SR 142948A is a potent neurotensin receptor antagonist that affects the expression of c-Fos and has properties of antipsychotic agent. It blocks hypothermia and analgesia induced by neurotensin. It blocks the increase in the concentration of Ca⁺² induced by the activation of phospholipase C in CHO cell model.

Features and Benefits

This compound is featured on the Neurotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

D Gully et al.

The Journal of pharmacology and experimental therapeutics, 280(2), 802-812 (1997-02-01)

SR 142948A, 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylc arbamoyl)-2-isopropylphenyl)-1H-pyrazole3-carbonyl]amino] adamantane-2-carboxylic acid, hydrochloride, a new and extremely potent neurotensin (NT) receptor antagonist, has been characterized in comparison with SR 48692. This selective compound possesses nanomolar affinities for NT receptors, recognizes the two binding sites described for

Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.

Elisabeth B Binder et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 29(12), 2200-2207 (2004-08-26)

Antipsychotic drugs (APDs) have previously been shown to alter Fos expression in a regionally specific manner. Increases in Fos expression in the nucleus accumbens (NAcc) are common to all clinically effective APDs. In contrast, APD-induced Fos expression increases in the

Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells.

Ulrike Olszewski et al.

Molecular oncology, 3(3), 204-213 (2009-04-28)

Pancreatic adenocarcinomas express neurotensin receptors in up to 90% of cases, however, their role in tumor biology and as a drug target is not clear. In the present study, a stable neurotensin (NT) analog induced intracellular calcium release and intracellular

Global Trade Item Number

SKU	GTIN
SML0015-25MG	04061832899527
SML0015-5MG	04061832899534

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service